CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 450 enrolled
Drug / intervention
IntelliSpace Cognition (ISC) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03801382
NCT03801382N/ACompleted

Study to Establish the Psychometric Properties of the Digital Cognitive Tests on the Philips IntelliSpace Cognition Platform

Philips Electronics Nederland B.V. acting through Philips CTO organization·interventional·Posted Jan 11, 2019·Updated Jun 22, 2023

In Brief

A clinical study evaluating IntelliSpace Cognition (ISC) and Paper-Pencil Tests for Cognitive Functioning of Healthy Individuals. Completed, enrolled 450 participants across 1 site.

Detailed Summary

This study aims to validate the tests that are on the IntelliSpace Cognition platform and to establish normative data for these tests.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 11, 2019
Enrollment StartApr 15, 2019
Primary CompletionAug 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.5 years ago

Interventions

IntelliSpace Cognition (ISC)device

Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.

Paper-Pencil Testsother

The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.